M

Medicines Evaluation Unit | Manchester, England

Research site

(Unclaimed)

Location

Langley Building Southmoor Road, Manchester, Manchester, England

Site insights

Top conditions

Top treatments

RPL554

Glycopyrrolate

AERO-007

Formoterol

Tiotropium

Budesonide

CHF1535

CHF6001

PTI-428

Charcoal

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 70 total trials

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pul...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Other: Placebo

Drug: Verekitug

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.

Active, not recruiting

Asthma

COPD (Chronic Obstructive Pulmonary Disease)

Biological: GB-0895 (SC)

Drug: Placebo (SC)

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)

This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic o...

Enrolling

Lung Diseases, Obstructive

Lung Disease Chronic

Drug: AERO-002

Drug: AERO-001

RIG 101 Trial in Healthy Adults and Adults With Asthma

Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy

Enrolling

Healthy Adult Participants

Asthma Exacerbation

Drug: RIG-101

Other: Placebo

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (TRECONY)

This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. W...

Enrolling

Asthma

Drug: CHF5993 pMDI with HFA-134a

Drug: CHF5993 pMDI with HFA-152a